Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

Hefei Wen ([email protected]) is a faculty member in the Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and the Harvard Pilgrim Health ...

It might sound basic, but data shows that focusing on healthy food and structured exercise might help patients with cancer live longer or respond to therapy. Other cancer news reports on immunotherapy ...

A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, ...

According to a McKinsey analysis, women spend 25% more time than men in poor health — and investments addressing the women’s ...

A diet that replaces animal products with plant-based foods—whether unprocessed or ultra-processed—and includes soybeans can ...

When the FDA approved fezolinetant for treating moderate to severe hot flashes in menopausal women, the news made headlines.

For women at higher risk of breast cancer, there is a proven way to cut the risk in half: take an anti-cancer drug such as ...

“BRI has been found to be superior in estimating risk for clinical endpoints including cardiometabolic disease, kidney ...